Those with known sensitivities to sulfur-containing compounds should exercise particular caution
According to clinical trial data from the STEP trials, 43.9% of patients taking semaglutide 2.4 mg experienced nausea at some point during treatment, with the majority of episodes occurring during or immediately after dose increases
Antioxidants (Basel, Switzerland)
In this trial, over 3,000 patients with type 2 diabetes and established cardiovascular disease or at high cardiovascular risk were randomized to receive either semaglutide or a placebo
If you prefer evening supplementation and experience no sleep disturbances, there is no medical reason to change your routine
Limitations of Cross-Trial Comparisons While retatrutides 28% threshold outpaces tirzepatides 22.5% threshold, medical researchers exercise caution when making direct comparisons